research An Occult Leydig Cell Tumour in a Postmenopausal Woman Presenting with Alopecia and Hirsutism: A Case Report
Surgery removed an ovarian tumor, improving her symptoms and normalizing testosterone levels.
Search
for
Sort by
Research
90-120 / 1000+ resultsresearch Skin cancer risk in alopecia areata: a systematic review and meta-analysis
Alopecia areata may lower melanoma risk and does not increase overall skin cancer risk.
research The patient outcomes with EGFR-mutated advanced non-small-cell lung cancer receiving aumolertinib as first-line treatment.
Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.
research Alopecia/hair loss in all patients treated with trastuzumab and paclitaxel: myth or reality?
Most patients treated with trastuzumab and paclitaxel experience some hair loss, but it's usually not severe.
research Alopecia in patients treated with molecularly targeted anticancer therapies
Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.
research Fatal Toxic Epidermal Necrolysis Associated With Cetuximab in a Patient With Colon Cancer
A cancer patient died from a severe skin reaction after taking the drug cetuximab.
research Patient-reported outcome assessment and objective evaluation of chemotherapy-induced alopecia
The Hair Check tool can measure hair loss, but patients' own reports are more reliable for assessing hair loss during chemotherapy.
research Beyond cancer treatment: dermo-aesthetic and other wellness recommendations for breast cancer patients
Breast cancer patients should balance treatment with safe wellness practices to improve quality of life, consulting their oncologist first.
research Three-dimensional models: from cell culture to Patient-Derived Organoid and its application to future liposarcoma research
3D models and organoids improve liposarcoma research and therapy development.
research Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
Neoadjuvant endocrine therapy led to a better future outlook than chemotherapy, with no major quality of life differences.
research Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study.
Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
research Management of Older Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario
Older patients with advanced kidney cancer can be managed with a drug called Sunitinib.
research Management of Sexual Dysfunction in Postmenopausal Breast Cancer Patients Taking Adjuvant Aromatase Inhibitor Therapy
Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.
research Patient Selection, Hair Transplant Design, and Hairstyle
Dr. Norwood's analysis highlights the need for careful patient selection and strategic hair transplant design to create a natural-looking hair density.
research Diagnostic Value of VDR in Bone Metastasis and Prognosis of Patients with Breast Cancer and Expression Correlation between Vitamin D Receptor and Hairless Protein
Low Vitamin D receptor levels in breast cancer are linked to worse outcomes and more bone metastases, and could be a marker for prognosis.
research Taxane-induced alopecia: A historical review of patients with ovarian or breast cancer treated with with paclitaxel, docetaxel or paclitaxel poliglumex
PPX causes much less hair loss than traditional taxanes.
research Off-label prescriptions: patient safety first
Off-label drug use can be risky and requires careful consideration to ensure patient safety.
research Abnormal hair growth in patients (pts) with metastatic colorectal cancer (mCRC) treated with the anti-epidermal growth factor receptor (EGFr) monoclonal antibody (mAb) panitumumab (Pmab)
Panitumumab treatment can cause unusual hair growth in some colorectal cancer patients.
research 532P Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)
Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
research The effects of low-dose radiation therapy in patients with mild-to-moderate Alzheimer's dementia: an interim analysis of a pilot study
Low-dose radiation therapy may improve brain function in some Alzheimer's patients and is generally well-tolerated.
research Three Cases of Hemodialysis Patients with Advanced Gastric Cancer Treated with Paclitaxel and Nab Paclitaxel
Paclitaxel and nab-paclitaxel can be safe and effective for advanced gastric cancer patients on hemodialysis.
research Patient-reported outcomes following various incision techniques in breast reconstruction: an observational cohort study in China
Endoscopic-assisted surgery leads to higher patient satisfaction in breast reconstruction.
research Effectiveness and safety of standard chemotherapy in older patients with ovarian cancer: a retrospective analysis by age group and treatment regimen
Older ovarian cancer patients live longer and tolerate weekly chemotherapy better than three-weekly treatments.
research Persistent radiation-induced alopecia in patients with central nervous system tumors and head and neck sarcomas.
Radiation therapy with chemotherapy can cause severe, long-lasting hair loss.
research Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany
This study observed the real-world safety and effectiveness of sacituzumab govitecan in 43 patients with metastatic triple-negative breast cancer at a German breast cancer center. Patients received a median of 5 cycles of treatment and were followed for a median of 12.9 months. Common adverse events included alopecia (90.7%), diarrhoea (37.2%), and fatigue (34.9%). Severe adverse events included neutropenia (27.9%) and diarrhoea (18.6%). Dose adjustments were necessary for 25 patients due to adverse events or pre-existing conditions. The median progression-free survival was 5.0 months, and the median overall survival was 13.1 months. The findings aligned with clinical trial data, but further studies were suggested to optimize treatment and manage adverse events.
research Erlotinib-Associated Alopecia in a Lung Cancer Patient
Erlotinib can cause significant but temporary hair loss in lung cancer patients.
research Incidence of alopecia in brain tumour patients treated with pencil scanning proton therapy and validation of existing NTCP models
A standardized scoring system is needed to improve model reliability for predicting hair loss in brain tumor patients treated with proton therapy.
research Care for alopecia during chemotherapy of cancer patients
The document concluded that there were no effective ways to prevent hair loss from chemotherapy but treatments were being explored.
research Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients
Some breast cancer chemotherapy can cause permanent hair loss.
research First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.